Download presentation
Presentation is loading. Please wait.
Published byHubert Grant Modified over 8 years ago
1
Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: Randomized Trial of Paclitaxel- Versus Sirolimus-Eluting Stents for Treatment of Coronary Restenosis in Sirolimus-Eluting Stents: The ISAR-DESIRE 2 (Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis 2) Study J Am Coll Cardiol. 2010;55(24):2710-2716. doi:10.1016/j.jacc.2010.02.009 Cumulative Frequency Distribution Curves for In-Stent Late Luminal Loss The gold line indicates paclitaxel-eluting stents (PES); the blue line indicates sirolimus-eluting stents (SES). Figure Legend:
2
Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: Randomized Trial of Paclitaxel- Versus Sirolimus-Eluting Stents for Treatment of Coronary Restenosis in Sirolimus-Eluting Stents: The ISAR-DESIRE 2 (Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis 2) Study J Am Coll Cardiol. 2010;55(24):2710-2716. doi:10.1016/j.jacc.2010.02.009 Angiographic Restenosis at 6 to 8 Months and Clinical Restenosis at 1 Year The blue bars indicate SES; the gold bars indicate PES. Clinical restenosis refers to target lesion revascularization. Abbreviations as in Figure 1. Figure Legend:
3
Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: Randomized Trial of Paclitaxel- Versus Sirolimus-Eluting Stents for Treatment of Coronary Restenosis in Sirolimus-Eluting Stents: The ISAR-DESIRE 2 (Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis 2) Study J Am Coll Cardiol. 2010;55(24):2710-2716. doi:10.1016/j.jacc.2010.02.009 Composite of Death, MI, or TLR The gold line indicates PES; the blue line indicates SES. MI = myocardial infarction; TLR = target lesion revascularization; other abbreviations as in Figure 1. Figure Legend:
Similar presentations
© 2025 SlidePlayer.com Inc.
All rights reserved.